Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Titan FCOI Policy
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
  • Search

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Publications
  • Posters
  • Media Resources

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

December 16, 2020

Titan Pharmaceuticals Announces Reverse Stock Split

November 30, 2020

Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 16, 2020

Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09

November 2, 2020

Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

October 28, 2020

Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

October 28, 2020

Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

October 26, 2020

Titan Pharmaceuticals Provides a Strategic & Corporate Update

October 15, 2020

Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering

September 24, 2020

Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

September 18, 2020

  • 1
  • 2
  • 3
  • Next »
© 2022 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap